ArticleNaunyn-Schmiedeberg's archives of pharmacology2013
Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Cold Exposure Drives Weight Gain and Adiposity following Chronic Suppression of Brown Adipose Tissue.International journal of molecular sciences · 2022Article
- The novel anti-colitic effect of β-adrenergic receptorsFrontiers in pharmacology · 2022Article
- Mirabegron in the Management of Overactive Bladder Syndrome.International journal of women's health · 2022Review
- Solifenacin/Mirabegron Induces an Acute Compliance Increase in the Filling Phase of the Capacity-Reduced Urinary Bladder: A Pressure-Volume Analysis in Rats.Frontiers in pharmacology · 2021Article
- The effect of mirabegron on bladder blood flow in a rat model of bladder outlet obstruction.World journal of urology · 2020Article
- βBritish journal of pharmacology · 2020Article
- βBritish journal of pharmacology · 2019Review
- Innovative pharmacotherapies for women with overactive bladder: where are we now and what is in the pipeline?International urogynecology journal · 2015Review
- Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys.Naunyn-Schmiedeberg's archives of pharmacology · 2013Article
- β3-receptor agonists for overactive bladder--new frontier or more of the same?Current urology reports · 2013Review
- Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome.Naunyn-Schmiedeberg's archives of pharmacology · 2013Article
- New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.Therapeutics and clinical risk management · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mirabegron, a selective β(3)-adrenoceptor agonist, facilitates urine storage function by exerting a relaxing effect on bladder smooth muscle. Here, we investigated the effect of mirabegron on bladder function during the storage phase. We assessed the effect of mirabegron on the resting intravesical pressure in anesthetized rats and also tested antimuscarinics (oxybutynin and tolterodine) under the same experimental conditions. Mirabegron dose-dependently decreased the resting intravesical pressure, while oxybutynin and tolterodine showed no statistically significant effects on resting intravesical pressure. We also investigated the effect of mirabegron on bladder function using cystometry technique in conscious rats with bladder outlet obstruction. While mirabegron dose-dependently decreased the frequency of nonvoiding contractions, considered an index of abnormal response in bladder storage, no significant effects were noted on the amplitude of nonvoiding contractions, micturition pressure, threshold pressure, voided volume, residual volume, or bladder capacity. Neither oxybutynin nor tolterodine affected the frequency of nonvoiding contractions; however, oxybutynin increased residual volume and tended to decrease voided volume in a dose-dependent manner, and tolterodine dose-dependently decreased voided volume. Taken together, these results shed light on the suggestion of mirabegron as a therapeutic agent, compared with antimuscarinics, with its most prominent effect being the facilitation of bladder storage.
Indexed as
Identifiers
23224420What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.